Home Cart Sign in  
Chemical Structure| 51987-99-6 Chemical Structure| 51987-99-6

Structure of TGN020
CAS No.: 51987-99-6

Chemical Structure| 51987-99-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of TGN020

CAS No. :51987-99-6
Formula : C8H6N4OS
M.W : 206.22
SMILES Code : O=C(NC1=NN=CS1)C2=CN=CC=C2
MDL No. :MFCD00708771
InChI Key :AGEGZHOPKZFKBP-UHFFFAOYSA-N
Pubchem ID :4173511

Safety of TGN020

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Astrocytes in rat supraoptic nucleus brain slices 10 µM 10 minutes To investigate the inhibitory effect of TGN-020 on VP neuronal activity under hyposmotic challenge. Results showed that TGN-020 blocked the rebound increase in firing rate of VP neurons induced by HOC. Acta Physiol (Oxf). 2021 Jul;232(3):e13672
Primary astrocytes 10 µM 24 or 48 hours TGN020 changed cell morphology, diminished cell proliferation and suppressed astrocyte activation Neurotherapeutics. 2024 Mar;21(2):e00306
Astrocytes in brain slices 10 µM 30 minutes To study the effect of TGN-020 on GFAP and AQP4 expression under OGD conditions, results showed that TGN-020 could partially block the OGD-induced decrease in GFAP expression. ASN Neuro. 2020 Jan-Dec;12:1759091420960550

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Wistar rats Streptozotocin-induced diabetic rat model Intravitreal injection 0.02 mg/μL Single injection, evaluated after 48 hours To investigate the effects of TGN-020 on diabetic retinal edema. Results showed that TGN-020 suppressed the expression of VEGF and AQP4 in diabetic rat retinas, reduced retinal thickness and vascular leakage. Int J Mol Sci. 2020 Mar 27;21(7):2324
Wistar rats Middle cerebral artery occlusion (MCAO) model Microinjection into the SON 10 μM Single injection, observation for 8 hours To study the effect of TGN-020 on MCAO-induced brain injury, results showed that TGN-020 could reduce MCAO-induced increases in pERK1/2 and AQP4 expression and decrease in GFAP expression. ASN Neuro. 2020 Jan-Dec;12:1759091420960550
C57BL/6 mice MPTP-induced PD mouse model Intraperitoneal injection 100 mg/kg Single administration To evaluate the inhibitory effect of TGN020 on AQP4 in the MPTP-induced PD mouse model and its impact on neuropathology. Results showed that TGN020 inhibited AQP4 expression, exacerbated astrogliosis, and further aggravated PD pathological manifestations. J Adv Res. 2024 Feb;56:125-136
Male C57BL/6 mice Collagenase-induced intracranial hemorrhage model Intraperitoneal injection 100 mg/kg 30 minutes before each exosomes administration, continued until the end of the experiment To evaluate the effect of TGN020 as an AQP4-specific inhibitor on H-Exo's promotion of intracranial lymphatic drainage and neurological recovery. Results showed that TGN020 successfully reversed H-Exo's ability to promote solute efflux and neurological recovery, indicating that H-Exo's effects depend on intact GLS function. Fluids Barriers CNS. 2025 Apr 14;22(1):37
Sprague-Dawley rats T13 spinal cord hemisection model Intrathecal injection 15 μg Once a day for 7 consecutive days TGN020 suppressed astrocyte activation, attenuated the development and maintenance of below-level CNP and promoted motor function recovery in vivo Neurotherapeutics. 2024 Mar;21(2):e00306
Male Sprague-Dawley rats Hyposmotic challenge model Intraperitoneal injection 20 mL/kg Single injection, lasting 10-30 minutes To investigate the regulatory effect of TGN-020 on VP neuronal activity under hyposmotic challenge in vivo. Results showed that TGN-020 blocked the rebound increase in firing rate of VP neurons induced by hyposmotic challenge. Acta Physiol (Oxf). 2021 Jul;232(3):e13672
Mice C57BL/6 mice Superfusion 20 μM Continuous superfusion TGN-020 was used to block AQP4 water channels to investigate its effect on light-evoked ECS α decrease. The results showed that TGN-020 had no effect on the light-evoked ECS α decrease. Glia. 2022 Oct;70(10):1927-1937
C57BL/6J mice Traumatic brain injury (TBI) model Intraperitoneal injection 200 mg/kg Every 24 hours until mice sacrifice To evaluate the effect of TGN020 on BBB integrity and astrocyte function after TBI, results showed that TGN020 significantly downregulated AQP4 expression, optimized BBB integrity and astrocyte function Int J Biol Sci. 2022 Jan 1;18(1):441-458
Sprague-Dawley rats Middle cerebral artery occlusion (MCAO) model Intraperitoneal injection 200 mg/kg Single dose, administered 10 minutes after MCAO To evaluate the effect of TGN-020 on brain edema and infarct volume after cerebral ischemia. Results showed that the TGN-020-treated group exhibited reduced infarct volumes and brain swelling at 1 day and 14 days after stroke, and better neurological recovery at 14 days. Front Immunol. 2022 May 3;13:870029
C57/BL6 male mice Middle cerebral artery occlusion (MCAO) model Intraperitoneal injection 200 mg/kg Single dose, lasting 48 hours TGN-020 alleviates inflammation and apoptosis after cerebral ischemia-reperfusion injury by improving glymphatic function and inhibiting the ERK1/2 pathway. Mol Neurobiol. 2024 Feb;61(2):1175-1186
C57BL/6J mice Traumatic brain injury (TBI) model Intraperitoneal injection 200 mg/kg 22 consecutive days TGN-020 significantly reduced the water content in the hippocampus and cortex of TBI mice and improved cognitive abilities. Heliyon. 2023 Nov 13;9(11):e22035
Mice RTg4510 transgenic mice Intraperitoneal injection 250 mg/kg Single dose To assess the effect of AQP4 inhibitor TGN-020 on CSF-ISF exchange and tau clearance in the brain. Results showed that TGN-020 significantly inhibited CSF-ISF exchange and tau clearance. Brain. 2020 Aug 1;143(8):2576-2593
Mice Chronic cerebral hypoperfusion model Intraperitoneal injection 250 mg/kg Single dose Inhibits AQP4 polarity, disrupts the polarized distribution of AQP4 in astrocytes, thereby inhibiting glymphatic system function. Neurosci Bull. 2022 Feb;38(2):181-199
BALB/c mice DSS-induced experimental colitis model Intraperitoneal injection 250 mg/kg Once daily for 7 days TGN-020 treatment effectively alleviated DSS-induced experimental colitis in mice and reduced apoptosis of colon epithelial cells Cell Death Discov. 2022 Jun 28;8(1):298
C57BL/6 mice Perioperative neurocognitive disorder (PND) mouse model Intraperitoneal injection 250 mg/kg Single dose TGN-020 further aggravated AQP4 depolarization in the hippocampus of PND mice, leading to exacerbated neuroinflammation and cognitive dysfunction. J Cereb Blood Flow Metab. 2024 Aug;44(8):1450-1466
Mice Traumatic brain injury (TBI) model Intraperitoneal injection 250 mg/kg Single dose TGN-020, a specific inhibitor of AQP4, was used for pharmacological blocking of the glymphatic system. The results showed that TGN-020 effectively blocked the glymphatic transport of RITC-dextran. CNS Neurosci Ther. 2023 Dec;29(12):3876-3888
Male C57BL/6J mice Healthy mice Intraperitoneal injection 400 mg/kg Single dose, experiments conducted 30 minutes post-injection To investigate the effect of AQP4 inhibitor TGN-020 on Aβ40 clearance. Results showed that TGN-020 significantly increased perivascular accumulation of Aβ40, indicating impaired perivascular clearance of Aβ40 due to AQP4 inhibition. Mol Neurobiol. 2020 Nov;57(11):4720-4734
Mice Tau propagation model Intraperitoneal injection 50 mg/kg 3 doses/week for 10 weeks To investigate the impact of long-term AQP4 inhibition on tau propagation, results showed TGN-020 treatment increased tau aggregation and transhemispheric spread in the brain. Alzheimers Res Ther. 2024 Apr 5;16(1):71

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.85mL

0.97mL

0.48mL

24.25mL

4.85mL

2.42mL

48.49mL

9.70mL

4.85mL

 

Historical Records

Categories